Synthesis, crystal structure and initial biological evaluation of the new enantiomerically pure chiral palladium(II) complex trans-bis[endo-(1R)-1,7,7-trimethylbicyclo[2.2.1]-heptan-2-amino]palladium(II)dichloride

Eur J Med Chem. 2002 Nov;37(11):919-22. doi: 10.1016/s0223-5234(02)01415-0.

Abstract

The palladium(II) complex trans-bis[(R)-(+)-bornylamino]palladium(II) dichloride was synthesised and characterised. The solid state structure of the complex was determined by X-ray structure analysis. The compound crystallises in the monoclinic space group P2(1) with a=12.383(2), b=23.689(5), c=12.769(3) A, beta=93.25(3) degrees, and V=3739.6(13) A(3). The complex was tested for its cytotoxicity against L(929), K(562) and HeLa cell lines using the MTT assay technique. It is also tested for its anticomplementary activity using a test that detects complement proteins inhibition. These activities were compared with those of the reference standards, cisplatin, carboplatin and oxaliplatin. The significance of these results is given and discussed.

MeSH terms

  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Cell Division / drug effects
  • Crystallography, X-Ray
  • Humans
  • Inhibitory Concentration 50
  • Molecular Structure
  • Organometallic Compounds / chemical synthesis*
  • Organometallic Compounds / chemistry
  • Organometallic Compounds / pharmacology
  • Palladium / chemistry*
  • Palladium / pharmacology
  • Stereoisomerism
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Organometallic Compounds
  • Palladium